Cambridge, United Kingdom

Volker Germaschewski

USPTO Granted Patents = 10 

Average Co-Inventor Count = 8.3

ph-index = 5

Forward Citations = 167(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
10 patents (USPTO):

Title: The Innovative Journey of Volker Germaschewski in Cambridge, GB

Introduction

Volker Germaschewski is a notable inventor based in Cambridge, GB, renowned for his contributions to the field of biotechnology. With an impressive portfolio of 10 patents, he has made significant strides in the development of innovative therapeutic solutions. His work primarily focuses on novel antibodies that play a crucial role in immunotherapy.

Latest Patents

Germaschewski's latest patents include pioneering research on anti-PD-L1 antibodies. These groundbreaking inventions pertain to bispecific antibodies that possess a domain specifically targeting PD-L1, and encompass immunocytokines that fuse an anti-PD-L1 antibody to a cytokine such as IL-2. His patents also outline methods of treatment, various uses, and pharmaceutical compositions that incorporate these innovative antibodies, bispecific antibodies, and immunocytokines.

Career Highlights

Throughout his career, Germaschewski has demonstrated exceptional expertise in the biopharmaceutical sector. Currently, he is affiliated with Kymab Limited, a leading company in the field that focuses on the development of antibody therapies. His commitment to advancing medical science is evident through his numerous patents and the knowledge he brings to his research.

Collaborations

In addition to his individual achievements, Germaschewski collaborates with several esteemed colleagues, including Jamie Iain Campbell and Ian Kirby. This collaborative approach enhances the dynamic nature of his research, facilitating the exploration of diverse scientific perspectives and techniques.

Conclusion

Volker Germaschewski stands out as a key figure in the biotechnology arena. His inventions, particularly in the realm of anti-PD-L1 antibodies, signify a leap forward in immunotherapy. As he continues his work with Kymab Limited, his role as an inventor not only shapes the future of therapeutic interventions but also helps to inspire the next generation of scientists and inventors in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…